Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. and reminds investors of the December 2, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against the company [2][5]. Group 1: Allegations Against Molina - The complaint alleges that Molina and its executives violated federal securities laws by making false or misleading statements and failing to disclose material adverse facts regarding the company's medical cost trend assumptions [5]. - Specific allegations include a dislocation between premium rates and medical costs, dependence on low utilization of various health services for near-term growth, and the likelihood of substantial cuts to financial guidance for fiscal year 2025 [5]. Group 2: Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter financial results, revealing adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [6][7]. - The company cut its full-year 2025 adjusted earnings per share guidance by 10.2%, from at least $24.50 to a range of $21.50 to $22.50, leading to a stock price drop of $6.97, or 2.9%, to close at $232.61 [7]. - On July 23, 2025, Molina further slashed its full-year 2025 earnings guidance, reporting GAAP net income of $4.75 per diluted share for the second quarter, an 8% year-over-year decrease, and cutting its full-year adjusted earnings guidance to no less than $19.00 per diluted share, resulting in a stock price decline of $32.03, or 16.84%, to close at $158.22 [8]. Group 3: Legal Proceedings and Investor Actions - The court-appointed lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [9]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [9]. - Faruqi & Faruqi encourages anyone with information regarding Molina's conduct to contact the firm, including whistleblowers and former employees [10].

New York, New York--(Newsfile Corp. - November 11, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Molina Healthcare, Inc. ("Molina Healthcare, Inc.") (NYSE: MOH) concerning possible violations of federal securities laws.On October 23, 2025, Molina published its third quarter, fiscal 2025 earnings well below consensus and slashed its guidance for the third time this year, citing cost pressure and underperformance. The Company is now expecting earnings of $14 per share ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Molina Healthcare, Inc. securities between February 5, 2025, and July 23, 2025, of the December 2, 2025, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Molina securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by December 2, 2025, to serve as lead plaintiff [2]. - The lawsuit alleges that Molina failed to disclose several material adverse facts regarding its financial health and operational assumptions, which misled investors [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [3]. - The firm achieved the largest securities class action settlement against a Chinese company at the time and has consistently ranked among the top firms for securities class action settlements since 2013 [3]. - In 2019, Rosen Law Firm secured over $438 million for investors, showcasing its effectiveness in litigation [3].

Core Insights - Molina Healthcare stock (NYSE: MOH) has experienced a decline of approximately 27% over the past month due to significant negative developments following its Q3 2025 report, yet it remains a potential investment opportunity due to historical rebound patterns [2][5] Financial Performance - Q3 profitability has substantially decreased, leading to a cut in the full-year earnings forecast [5] - Revenue growth has been reported at 13.7% for the last twelve months (LTM) and an average of 12.8% over the last three years [6] - The minimum annual revenue growth in the last three years was 6.7% [6] - The stock trades at a price-to-earnings (PE) multiple of 8.4 [6] Operational Challenges - Rising medical costs within the Marketplace business segment are a concern [5] - The company faces external pressures from market anxiety regarding new regulatory proposals and several shareholder lawsuits [5] Market Position - The stock is currently trading within a historically significant support range of $133.85 to $147.95, where it has attracted strong buying interest on three separate occasions over the last decade [5] - Following previous rebounds from this support range, MOH stock has generated an average peak return of 75.7% [5] Cash Flow Metrics - The company has reported a nearly -1.3% free cash flow margin and a 3.0% operating margin for the last twelve months [6]

Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. to secure legal counsel before the December 2, 2025 deadline for a securities class action lawsuit related to undisclosed adverse facts affecting the company's financial guidance and operations [1][5]. Group 1: Class Action Details - The class period for the lawsuit is from February 5, 2025, to July 23, 2025, and investors who purchased securities during this time may be entitled to compensation without upfront costs [1][2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by December 2, 2025 [3][6]. Group 2: Allegations Against Molina Healthcare - The lawsuit alleges that Molina failed to disclose critical information regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [5]. - It is claimed that Molina's near-term growth relied on a lack of utilization of various health services, which could lead to a significant cut in financial guidance for fiscal year 2025 [5]. - The lawsuit asserts that the positive statements made by Molina regarding its business and prospects were materially misleading due to the undisclosed adverse facts [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Insights - Molina Healthcare, Inc. is under investigation for possible violations of federal securities laws following disappointing earnings and guidance cuts [1][2] - The company reported third quarter fiscal 2025 earnings significantly below consensus, with an expected full-year earnings of $14 per share, down from a previous estimate of "no less than $19" [2] - Molina's stock price dropped by $38.08 to open at $157.05 per share after the earnings announcement [3] Financial Performance - Molina's third quarter earnings were well below market expectations, primarily due to cost pressures and underperformance in its marketplace business [2] - The company has revised its earnings guidance for the third time in 2025, indicating ongoing financial challenges [2] Stock Market Reaction - Following the earnings report, Molina's stock experienced a significant decline, reflecting investor concerns over the company's financial outlook [3]

Core Insights - President Donald Trump's comments regarding federal health care funding have led to a decline in shares of health insurers, suggesting a potential shift in the Affordable Care Act (ACA) funding structure [1][4]. Group 1: Market Reaction - Centene (CNC), HCA Healthcare (HCA), and Molina Healthcare (MOH) experienced significant stock declines, with Centene down over 8%, Molina nearly 7%, and HCA dropping 5% [5]. - Other health insurers, including United Health Group (UNH) and Cigna Group (CI), also saw their shares fall following Trump's remarks [5]. Group 2: Policy Implications - Trump proposed that federal health care funds should be redirected to individuals rather than insurers, which could fundamentally alter the ACA marketplace [2]. - The Committee for a Responsible Federal Budget estimated that federal subsidies to insurance companies this year amount to $138 billion, a substantial increase from $53 billion in 2020 [2][4].

Core Insights - Major health insurers' shares declined due to a Senate deal that ended a 40-day U.S. government shutdown but did not extend Affordable Care Act (ACA) subsidies, creating uncertainty for millions relying on these subsidies for health coverage [1][3] - The ongoing debate over ACA subsidies is politically charged, with a narrow window for lawmakers to act before the open enrollment period for 2026 coverage ends on January 15 [5] Group 1: Market Reaction - Health insurance stocks fell as investors assessed the implications of the political stalemate on the sector [1] - Key companies affected include Cigna Group, Centene Corp, CVS Health Inc, Elevance Health, Humana Inc, Molina Healthcare Inc, UnitedHealth Group Inc, HCA Healthcare, and Tenet Healthcare Corporation [2] Group 2: Legislative Context - A procedural vote passed 60-40, allowing for short-term funding through January 30, while delaying the ACA subsidy issue until December [3] - The temporary spending bill prevents federal agencies from terminating employees until January 30, which is seen as a victory for federal worker unions [4] Group 3: Potential Impact on Consumers - Without congressional action, approximately 24 million enrollees could face significant premium increases for their 2026 plans, with estimates suggesting monthly premiums for ACA plans could more than double if pandemic-era assistance is not extended [3]

Investors with a lot of money to spend have taken a bearish stance on Molina Healthcare (NYSE:MOH).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MOH, it often means somebody knows something is about to happen.So how do we know what these investors just did? Today, Benzinga's options scanner sp ...

Core Viewpoint - The stock prices of U.S. health insurance companies, particularly those heavily involved in the Affordable Care Act (Obamacare), have declined significantly following former President Donald Trump's statements advocating for direct federal funding to be given to individuals rather than insurance companies [1][2]. Group 1: Impact on Health Insurance Companies - Centene and Oscar Health led the decline in the U.S. healthcare sector, with stock prices dropping over 10% in pre-market trading, while other major insurers like Elevance Health and Molina Healthcare also experienced significant losses [2]. - Trump's comments suggest a shift in funding strategy that could severely impact the profitability of health insurance companies operating under the ACA framework, as federal funds may no longer support insurance premiums [1][4]. Group 2: Political Context and Proposals - A Republican proposal aims to redirect federal funds into flexible spending accounts for families instead of providing subsidies to insurance companies, potentially breaking the deadlock in the Senate regarding healthcare funding [3]. - Trump's rhetoric emphasizes a populist approach, advocating for direct financial support to citizens, which could undermine the Democratic Party's signature healthcare policy [4].